Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201
Relatively few coronavirus disease cases and deaths have been reported from sub-Saharan Africa, although the extent of its spread remains unclear. During August 10–September 11, 2020, we recruited 2,214 participants for a representative household-based cross-sectional serosurvey in Juba, South Sud...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Japan Cooperative Medical Sciences Program—Virtual Workshop
2021
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12493/516 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1800403069115039744 |
|---|---|
| author | Andrew, Baguma Juma John, Hassen Sheila, K. Baya Joseph, F. Wamala |
| author_facet | Andrew, Baguma Juma John, Hassen Sheila, K. Baya Joseph, F. Wamala |
| author_sort | Andrew, Baguma |
| collection | KAB-DR |
| description | Relatively few coronavirus disease cases and deaths have been reported from sub-Saharan Africa, although the extent
of its spread remains unclear. During August 10–September 11, 2020, we recruited 2,214 participants for a representative
household-based cross-sectional serosurvey in Juba, South Sudan. We found 22.3% of participants had severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) receptor binding domain IgG titers above prepandemic levels. After accounting for waning antibody levels, age, and sex, we estimated that 38.3% (95% credible interval 31.8%–46.5%) of the population had been infected with SARS-CoV-2. At this rate, for each PCR–confi rmed SARS-CoV-2 infection reported by the Ministry of Health, 103 (95% credible interval 86–126) infections would have been unreported, meaning SARS-CoV-2 has likely spread extensively within Juba. We also found diff erences in background reactivity in Juba compared with Boston, Massachusetts, USA, where the immunoassay was validated. Our fi ndings underscore the need to validate serologic tests in sub-Saharan Africa populations. |
| format | Article |
| id | oai:idr.kab.ac.ug:20.500.12493-516 |
| institution | KAB-DR |
| publishDate | 2021 |
| publisher | Japan Cooperative Medical Sciences Program—Virtual Workshop |
| record_format | dspace |
| spelling | oai:idr.kab.ac.ug:20.500.12493-5162024-01-17T04:44:49Z Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 Andrew, Baguma Juma John, Hassen Sheila, K. Baya Joseph, F. Wamala Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus Relatively few coronavirus disease cases and deaths have been reported from sub-Saharan Africa, although the extent of its spread remains unclear. During August 10–September 11, 2020, we recruited 2,214 participants for a representative household-based cross-sectional serosurvey in Juba, South Sudan. We found 22.3% of participants had severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) receptor binding domain IgG titers above prepandemic levels. After accounting for waning antibody levels, age, and sex, we estimated that 38.3% (95% credible interval 31.8%–46.5%) of the population had been infected with SARS-CoV-2. At this rate, for each PCR–confi rmed SARS-CoV-2 infection reported by the Ministry of Health, 103 (95% credible interval 86–126) infections would have been unreported, meaning SARS-CoV-2 has likely spread extensively within Juba. We also found diff erences in background reactivity in Juba compared with Boston, Massachusetts, USA, where the immunoassay was validated. Our fi ndings underscore the need to validate serologic tests in sub-Saharan Africa populations. Kabale University 2021-07-30T18:19:16Z 2021-07-30T18:19:16Z 2021 Article DOI: https://doi.org/10.3201/eid2706.210568 http://hdl.handle.net/20.500.12493/516 application/pdf Japan Cooperative Medical Sciences Program—Virtual Workshop |
| spellingShingle | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus Andrew, Baguma Juma John, Hassen Sheila, K. Baya Joseph, F. Wamala Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 |
| title | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 |
| title_full | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 |
| title_fullStr | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 |
| title_full_unstemmed | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 |
| title_short | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201 |
| title_sort | seroprevalence of severe acute respiratory syndrome coronavirus 2 igg in juba south sudan 20201 |
| topic | Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus |
| url | http://hdl.handle.net/20.500.12493/516 |
| work_keys_str_mv | AT andrewbaguma seroprevalenceofsevereacuterespiratorysyndromecoronavirus2igginjubasouthsudan20201 AT jumajohnhassen seroprevalenceofsevereacuterespiratorysyndromecoronavirus2igginjubasouthsudan20201 AT sheilakbaya seroprevalenceofsevereacuterespiratorysyndromecoronavirus2igginjubasouthsudan20201 AT josephfwamala seroprevalenceofsevereacuterespiratorysyndromecoronavirus2igginjubasouthsudan20201 |